Coronado Industries, Inc. said today that their Italian distributor will be displaying the company’s PNT technology at the International Congress of the Italian Society of Ophthalmology in Florence in
May 9, 2005 (Press Release) --
Fountain Hills, May 9, 2005 – Coronado Industries, Inc. (OTC BB: CDIK), the manufacturers of unique proprietary pneumatic devices for the non-invasive treatment of glaucoma through its wholly owned subsidiary, Ophthalmic International, said today that the company’s Italian distributor will be prominently displaying the company’s PNT technology at this year’s International Congress of the Italian Society of Ophthalmology in Florence on May 11 – 14. This annual meeting attracts Italy’s top ophthalmologists, doctors and opinion leaders as well as thought leaders from across Europe.
Eupharmed, s.r.l., the exclusive distributor of PNT in Italy, said the company’s booth and presentations would focus solely on the benefits and growing acceptance of PNT as an alternative approach for the treatment of glaucoma. Some of Italy’s leading glaucoma specialists who have experience with PNT will also be present at the meeting and will be discussing the positive results they are achieving with PNT.
Coronado’s Chairman, Richard Smith, said that the significant efforts and investments made by Eupharmed in order to prominently position PNT at this year’s Italian Congress again confirms the strong belief they have in the product.. PNT is an important product for them and their continued focus towards expanding the market for PNT is another validation of them being the right partner for us.
Mr. Smith said that Coronado was moving ahead rapidly in securing additional distribution contracts in Europe which he expected would provide for further sales of additional PNT controllers which, in turn, will increase ring sales.
Dr. John Sharkey, President of Ophthalmic International and Director of Operations for Coronado, said that a core component of Eupharmed’s strategy was facilitating interaction between ophthalmologists so that they could discuss PNT with their peers. “We are especially happy to note that Italian physicians will have several opportunities to discuss the positive results they have had in using the PNT treatment. Their opinion, coupled with the recent publication of our first PNT manuscript in The Annals of Ophthalmology and our upcoming publication in the European Journal of Ophthalmology, provides considerable support to our partners marketing efforts in Italy and across Europe,” he said
Coronado Industries through its wholly owned subsidiary, Ophthalmic International, is focused on the development and commercialization of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma which are open angle and pigmentary as well as for the treatment of ocular hypertension
###
Contact: Bob Smith, Investor Relations Victor Webb/Madlene Olson, Media
Coronado Industries Marston Webb International
1 (480) 837-6810 1 (212) 684-6601
Forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company’s products, increased levels of competition for the company, and new products and technological changes.
Eupharmed, s.r.l., the exclusive distributor of PNT in Italy, said the company’s booth and presentations would focus solely on the benefits and growing acceptance of PNT as an alternative approach for the treatment of glaucoma. Some of Italy’s leading glaucoma specialists who have experience with PNT will also be present at the meeting and will be discussing the positive results they are achieving with PNT.
Coronado’s Chairman, Richard Smith, said that the significant efforts and investments made by Eupharmed in order to prominently position PNT at this year’s Italian Congress again confirms the strong belief they have in the product.. PNT is an important product for them and their continued focus towards expanding the market for PNT is another validation of them being the right partner for us.
Mr. Smith said that Coronado was moving ahead rapidly in securing additional distribution contracts in Europe which he expected would provide for further sales of additional PNT controllers which, in turn, will increase ring sales.
Dr. John Sharkey, President of Ophthalmic International and Director of Operations for Coronado, said that a core component of Eupharmed’s strategy was facilitating interaction between ophthalmologists so that they could discuss PNT with their peers. “We are especially happy to note that Italian physicians will have several opportunities to discuss the positive results they have had in using the PNT treatment. Their opinion, coupled with the recent publication of our first PNT manuscript in The Annals of Ophthalmology and our upcoming publication in the European Journal of Ophthalmology, provides considerable support to our partners marketing efforts in Italy and across Europe,” he said
Coronado Industries through its wholly owned subsidiary, Ophthalmic International, is focused on the development and commercialization of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma which are open angle and pigmentary as well as for the treatment of ocular hypertension
###
Contact: Bob Smith, Investor Relations Victor Webb/Madlene Olson, Media
Coronado Industries Marston Webb International
1 (480) 837-6810 1 (212) 684-6601
Forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company’s products, increased levels of competition for the company, and new products and technological changes.
Email
Print
SPAM
